Literature DB >> 18267072

Adenovirus serotype 5 hexon mediates liver gene transfer.

Simon N Waddington1, John H McVey, David Bhella, Alan L Parker, Kristeen Barker, Hideko Atoda, Rebecca Pink, Suzanne M K Buckley, Jenny A Greig, Laura Denby, Jerome Custers, Takashi Morita, Ivo M B Francischetti, Robson Q Monteiro, Dan H Barouch, Nico van Rooijen, Claudio Napoli, Menzo J E Havenga, Stuart A Nicklin, Andrew H Baker.   

Abstract

Adenoviruses are used extensively as gene transfer agents, both experimentally and clinically. However, targeting of liver cells by adenoviruses compromises their potential efficacy. In cell culture, the adenovirus serotype 5 fiber protein engages the coxsackievirus and adenovirus receptor (CAR) to bind cells. Paradoxically, following intravascular delivery, CAR is not used for liver transduction, implicating alternate pathways. Recently, we demonstrated that coagulation factor (F)X directly binds adenovirus leading to liver infection. Here, we show that FX binds to the Ad5 hexon, not fiber, via an interaction between the FX Gla domain and hypervariable regions of the hexon surface. Binding occurs in multiple human adenovirus serotypes. Liver infection by the FX-Ad5 complex is mediated through a heparin-binding exosite in the FX serine protease domain. This study reveals an unanticipated function for hexon in mediating liver gene transfer in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18267072     DOI: 10.1016/j.cell.2008.01.016

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  308 in total

Review 1.  Gene therapy: light is finally in the tunnel.

Authors:  Huibi Cao; Robert S Molday; Jim Hu
Journal:  Protein Cell       Date:  2012-01-10       Impact factor: 14.870

2.  Magnetic nanoparticles enhance adenovirus transduction in vitro and in vivo.

Authors:  Cédric Sapet; Christophe Pellegrino; Nicolas Laurent; Flavie Sicard; Olivier Zelphati
Journal:  Pharm Res       Date:  2011-12-07       Impact factor: 4.200

3.  Gene therapy to the kidney using viral vectors.

Authors:  Talha Akbulut; Frank Park
Journal:  Paidiatrike       Date:  2008

4.  Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors.

Authors:  Raul Alba; Angela C Bradshaw; Lynda Coughlan; Laura Denby; Robert A McDonald; Simon N Waddington; Suzanne M K Buckley; Jenny A Greig; Alan L Parker; Ashley M Miller; Hongjie Wang; Andre Lieber; Nico van Rooijen; John H McVey; Stuart A Nicklin; Andrew H Baker
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

5.  Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.

Authors:  Di Yu; Chuan Jin; Justyna Leja; Nadim Majdalani; Berith Nilsson; Fredrik Eriksson; Magnus Essand
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

6.  Construction of metabolically biotinylated adenovirus with deleted fiber knob as targeting vector.

Authors:  Yanzheng Liu; Philippe Valadon; Jan E Schnitzer
Journal:  Virol J       Date:  2010-11-12       Impact factor: 4.099

Review 7.  Innate immunity to adenovirus: lessons from mice.

Authors:  Svetlana Atasheva; Jia Yao; Dmitry M Shayakhmetov
Journal:  FEBS Lett       Date:  2019-12-08       Impact factor: 4.124

8.  Usage of integrin and heparan sulfate as receptors for mouse adenovirus type 1.

Authors:  Sharmila Raman; Tien-Huei Hsu; Shanna L Ashley; Katherine R Spindler
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

9.  Circulating antibodies and macrophages as modulators of adenovirus pharmacology.

Authors:  Reeti Khare; Matthew L Hillestad; Zhili Xu; Andrew P Byrnes; Michael A Barry
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

10.  Retargeting of gene expression using endothelium specific hexon modified adenoviral vector.

Authors:  Sergey A Kaliberov; Lyudmila N Kaliberova; Zhi Hong Lu; Meredith A Preuss; Justin A Barnes; Cecil R Stockard; William E Grizzle; Jeffrey M Arbeit; David T Curiel
Journal:  Virology       Date:  2013-10-15       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.